NCT03465774 is a clinical trial of Doxycycline in Pleural Neoplasm, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT03465774?

NCT03465774 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT03465774?

Interventions in NCT03465774: Doxycycline, Indwelling Catheter, Quality-of-Life Assessment, Questionnaire Administration, Survey Administration.

What condition does NCT03465774 study?

NCT03465774 studies Pleural Neoplasm.

Is NCT03465774 still recruiting?

NCT03465774 is currently recruiting now. Last updated 5 March 2026.

Last reviewed 2026-03-05 · How we verify

NCT03465774

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Indwelling Pleural Catheters With or Without Doxycycline in Treating Patients With Malignant Pleural Effusions

Recruiting now Last updated 5 March 2026

What this trial tests

trial testing Doxycycline in Pleural Neoplasm in 208 participants. Currently enrolling.

Timeline

8 March 2018

Primary endpoint
1 December 2028

1 December 2028

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	208
Start date	8 March 2018
Primary completion	1 December 2028
Estimated completion	1 December 2028
Sites	1 location across United States

Drugs / interventions tested

Doxycycline (doxycycline) — full drug profile →
Indwelling Catheter
Quality-of-Life Assessment
Questionnaire Administration
Survey Administration

Conditions studied

Pleural Neoplasm — all drugs for Pleural Neoplasm →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Pleural Neoplasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is designed to obtain preliminary data comparing indwelling pleural catheters (IPCs) versus IPCs plus doxycycline for pleurodesis as treatments for malignant pleural effusion (MPE). Indwelling pleural catheters (IPCs) are commonly used to treat pleural effusions (build-up of fluid in the lungs). Doxycycline is an antibiotic that is also used to treat pleural effusions. The goal of this clinical research study is to learn if adding doxycycline to the use of an IPC can lead to shorter treatment times with IPCs.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

New drugs are not enough‑drug repositioning in oncology: An update.
Armando RG, Mengual Gómez DL, Gomez DE. · · 2020 · cited 72× · PMID 32124955 · DOI 10.3892/ijo.2020.4966
Metabolic vulnerability of cancer stem cells and their niche.
Marrone L, Romano S, Malasomma C, Di Giacomo V, et al · · 2024 · cited 3× · PMID 38659591 · DOI 10.3389/fphar.2024.1375993

Verify or expand the search:

Other trials of Doxycycline

Trials testing the same drug.

NCT07306234 — Doxycycline vs. Macrolide for MRMP (DOMINO) · Phase 4 · not yet recruiting
NCT07230028 — Doxycycline Boosted Therapy in Lyme Borreliosis: DoBo Study. · Phase 4 · not yet recruiting
NCT07343635 — The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined · NA · recruiting
NCT07164131 — Azithromycin Versus Doxycycline in Hospitalized Adult Patients With Community Acquired Pneumonia Treated With Beta-lacta · Phase 4 · recruiting
NCT06915688 — A Study Comparing Doxycycline and Levofloxacin for Treating COPD Exacerbations · NA · not yet recruiting

Other recruiting trials for Pleural Neoplasm

Currently open trials in the same condition.

NCT05672108 — Phase II Trial of Lung Chemoemobolization · Phase 2 · recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03465774 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 5 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03465774.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing